Top

Published in:

01-11-2014 | Understanding the Disease

Understanding incretins

Authors: Adam M. Deane, Palle B. Jeppesen

Published in: Intensive Care Medicine | Issue 11/2014

Excerpt

The ‘incretin effect’ is the physiological phenomenon observed following ingestion of glucose that results in plasma insulin concentrations almost twofold greater than those measured after a comparable intravenous (IV) glucose stimulus [1]. This phenomenon proves that the gastrointestinal tract is pivotal in regulating insulin secretion and glycaemia. It is now understood that the incretin effect is due to two hormones, glucagon-like peptide 1 (GLP-1) and glucose-dependent insulinotropic peptide (GIP). …

Available only for authorised users

Plummer MP, Chapman MJ, Horowitz M, Deane AM (2014) Incretins and the intensivist: what are they and what does an intensivist need to know about them? Crit Care 18:R205CrossRef

Meloni AR, DeYoung MB, Lowe C, Parkes DG (2013) GLP-1 receptor activated insulin secretion from pancreatic beta-cells: mechanism and glucose dependence. Diabetes Obes Metab 15(1):15–27PubMedCrossRefPubMedCentral

Nauck MA, Heimesaat MM, Orskov C, Holst JJ, Ebert R, Creutzfeldt W (1993) Preserved incretin activity of glucagon-like peptide 1 [7-36 amide] but not of synthetic human gastric inhibitory polypeptide in patients with type-2 diabetes mellitus. J Clin Invest 91(1):301–307PubMedCrossRefPubMedCentral

Deacon CF, Mannucci E, Ahren B (2012) Glycaemic efficacy of glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors as add-on therapy to metformin in subjects with type 2 diabetes-a review and meta analysis. Diabetes Obes Metab 14(8):762–767PubMedCrossRef

Inzucchi SE, Bergenstal RM, Buse JB, Diamant M, Ferrannini E, Nauck M, Peters AL, Tsapas A, Wender R, Matthews DR (2012) Management of hyperglycemia in type 2 diabetes: a patient-centered approach: position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care 35(6):1364–1379PubMedCrossRefPubMedCentral

Madsen KB, Askov-Hansen C, Naimi RM, Brandt CF, Hartmann B, Holst JJ, Mortensen PB, Jeppesen PB (2013) Acute effects of continuous infusions of glucagon-like peptide (GLP)-1, GLP-2 and the combination (GLP-1 + GLP-2) on intestinal absorption in short bowel syndrome (SBS) patients. A placebo-controlled study. Regul Pept 184:30–39PubMedCrossRef

Krinsley JS, Egi M, Kiss A, Devendra AN, Schuetz P, Maurer PM, Schultz MJ, van Hooijdonk RT, Kiyoshi M, Mackenzie IM et al (2013) Diabetic status and the relation of the three domains of glycemic control to mortality in critically ill patients: an international multicenter cohort study. Crit Care 17(2):R37PubMedCrossRefPubMedCentral

Plummer MP, Bellomo R, Cousins CE, Annink CE, Sundararajan K, Reddi BA, Raj JP, Chapman MJ, Horowitz M, Deane AM (2014) Dysglycaemia in the critically ill and the interaction of chronic and acute glycaemia with mortality. Intensive Care Med 40(7):973–980PubMedCrossRef

Nauck MA, Baranov O, Ritzel RA, Meier JJ (2013) Do current incretin mimetics exploit the full therapeutic potential inherent in GLP-1 receptor stimulation? Diabetologia 56(9):1878–1883PubMedCrossRef

10.

Deane AM, Chapman MJ, Fraser RJ, Burgstad CM, Besanko LK, Horowitz M (2009) The effect of exogenous glucagon-like peptide-1 on the glycaemic response to small intestinal nutrient in the critically ill: a randomised double-blind placebo-controlled cross over study. Crit Care 13(3):R67PubMedCrossRefPubMedCentral

11.

Deane AM, Summers MJ, Zaknic AV, Chapman MJ, Fraser RJ, Di Bartolomeo AE, Wishart JM, Horowitz M (2011) Exogenous glucagon-like peptide-1 attenuates the glycaemic response to postpyloric nutrient infusion in critically ill patients with type-2 diabetes. Crit Care 15(1):R35PubMedCrossRefPubMedCentral

12.

Deane AM, Chapman MJ, Fraser RJ, Summers MJ, Zaknic AV, Storey JP, Jones KL, Rayner CK, Horowitz M (2010) Effects of exogenous glucagon-like peptide-1 on gastric emptying and glucose absorption in the critically ill: relationship to glycemia. Crit Care Med 38(5):1261–1269PubMed

13.

Umapathysivam MM, Lee MY, Jones KL, Annink CE, Cousins CE, Trahair LG, Rayner CK, Chapman MJ, Nauck MA, Horowitz M et al (2014) Comparative effects of prolonged and intermittent stimulation of the glucagon-like peptide 1 receptor on gastric emptying and glycemia. Diabetes 63(2):785–790PubMedCrossRef

14.

Abuannadi M, Kosiborod M, Riggs L, House JA, Hamburg MS, Kennedy KF, Marso SP (2013) Management of hyperglycemia with the administration of intravenous exenatide to patients in the cardiac intensive care unit. Endocr Pract 19(1):81–90PubMedCrossRef

15.

Galiatsatos P, Gibson BR, Rabiee A, Carlson O, Egan JM, Shannon RP, Andersen DK, Elahi D (2013) The glucoregulatory benefits of glucagon-like peptide-1 (7–36) amide infusion during intensive insulin therapy in critically ill surgical patients: a pilot study. Crit Care Med 42(3):638–645CrossRef

Title: Understanding incretins
Authors: Adam M. Deane
Palle B. Jeppesen
Publication date: 01-11-2014
Publisher: Springer Berlin Heidelberg
Published in: Intensive Care Medicine / Issue 11/2014
Print ISSN: 0342-4642
Electronic ISSN: 1432-1238
DOI: https://doi.org/10.1007/s00134-014-3435-0

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Understanding incretins

Excerpt

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Excerpt

Please log in to get access to this content

Other articles of this Issue 11/2014

Mechanisms of the effects of prone positioning in acute respiratory distress syndrome

Incidence and associated factors of difficult tracheal intubations in pediatric ICUs: a report from National Emergency Airway Registry for Children: NEAR4KIDS

Quality of dying in the intensive care unit: it’s a matter of time

Surviving Sepsis Campaign: association between performance metrics and outcomes in a 7.5-year study

Understanding clinical trials: emerging methodological issues

Myocardial viability in human septic heart